Cargando…

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Approximately 1–2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (OR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ackermann, Christoph Jakob, Stock, Gustavo, Tay, Rebecca, Dawod, Mohammed, Gomes, Fabio, Califano, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767757/ https://www.ncbi.nlm.nih.gov/pubmed/31576143 http://dx.doi.org/10.2147/OTT.S171665

Ejemplares similares

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

1p/19q codeletion and RET rearrangements in small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2016)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
por: Zhang, Kai, et al.
Publicado: (2019)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
por: Fu, Sha, et al.
Publicado: (2015)

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
por: Lu, Chang, et al.
Publicado: (2020)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis
por: Cyniak-Magierska, Anna, et al.
Publicado: (2011)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Low Frequency of Rearrangements of the ret and trk Proto‐oncogenes in Japanese Thyroid Papillary Carcinomas
por: Wajjwalku, Worawidh, et al.
Publicado: (1992)

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1b7iiv11s628609bun9c6dlr40